Company / Current Liabilities
Acadia Pharmaceuticals Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$277.1M
FY2025
5-year range
$96.1M / $394.9M
FY2021-FY2025
Trend
-29.8%
vs FY2024
Sector context
#51 of 213
Health Care
What the data says
Acadia Pharmaceuticals's current liabilities of $277M is higher than 76% of companies in the Health Care sector (FY2025). Current Liabilities has fluctuated over the past 10 years, ranging from $43M in FY2016 to $395M in FY2024.
Based on SEC 10-K filings.
$277M in FY2025 with a 5-year CAGR of +21.2%. Top quartile in the Health Care sector.
Increased from $254M to $277M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +30.2%
- 5-Year CAGR
- +21.2%
- 10-Year CAGR
- -
Sector benchmark
-82.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +21.2%, indicating consistent growth.
- In FY2025, current liabilities decreased 29.8% year-over-year.
- Ranks #51 out of 213 companies in the Health Care sector.
- Peak current liabilities was recorded in FY2024.
Company context
Key Data Points
- Strong profit margin: 24.9%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 28.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $277.1M | -29.8% |
| FY2024 | $394.9M | +55.3% |
| FY2023 | $254.3M | +102.4% |
| FY2022 | $125.6M | +30.8% |
| FY2021 | $96.1M | -9.3% |
| FY2020 | $106.0M | +41.6% |
| FY2019 | $74.8M | +25.6% |
| FY2018 | $59.6M | +21.5% |
| FY2017 | $49.0M | +15.1% |
| FY2016 | $42.6M | +94.4% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026